Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2017 16:05 ET | Source: TESARO, Inc.

TESARO Announces Third-Quarter 2017 Operating Results

ZEJULA® was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 millionPositive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-endExpansion of...
October 25, 2017 19:15 ET | Source: TESARO, Inc.

TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy

VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...
October 24, 2017 16:15 ET | Source: TESARO, Inc.

TESARO to Announce Third-Quarter 2017 Financial Results on November 7, 2017

WALTHAM, Mass., Oct. 24, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2017 financial results on Tuesday, November 7, 2017, after the close of the U.S....
October 23, 2017 16:15 ET | Source: TESARO, Inc.

TESARO Announces Participation at Two Investor Conferences

WALTHAM, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
October 18, 2017 08:00 ET | Source: TESARO, Inc.

The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer

CHICAGO and WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology, and TESARO, Inc. (NASDAQ:TSRO),...
September 28, 2017 16:30 ET | Source: TESARO, Inc.

TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller

WALTHAM, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today the availability of a number of new support resources...
September 15, 2017 07:45 ET | Source: TESARO, Inc.

TESARO Receives Positive CHMP Opinion for ZEJULA®

ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee...
September 11, 2017 08:00 ET | Source: TESARO, Inc.

TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting

MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody,...
August 25, 2017 08:01 ET | Source: TESARO, Inc.

TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting

WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data from nine abstracts will be presented at the...
August 23, 2017 16:15 ET | Source: TESARO, Inc.

TESARO Announces Participation at Four Investor Conferences

WALTHAM, Mass., Aug. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor...